PDF(Pubmed)
Abstract：
UNASSIGNED: Diffuse large B-cell lymphoma (DLBCL) is a kind of highly heterogeneous non-Hodgkin lymphoma, both in clinical and genetic terms. DLBCL is admittedly categorized into six subtypes by genetics, which contain MCD, BN2, EZB, N1, ST2, and A53. Dyslipidemia is relevant to a multitude of solid tumors and has recently been reported to be associated with hematologic malignancies. We aim to present a retrospective study investigating dyslipidemia in DLBCL based on the molecular subtypes.
UNASSIGNED: This study concluded that 259 patients with newly diagnosed DLBCL and their biopsy specimens were available for molecular typing. Results show that the incidence of dyslipidemia (87.0%, p <0.001) is higher in the EZB subtype than in others, especially hypertriglyceridemia (78.3%, p = 0.001) in the EZB subtype. Based on the pathological gene-sequencing, patients with BCL2 gene fusion mutation are significantly correlative with hyperlipidemia (76.5%, p = 0.006) and hypertriglyceridemia (88.2%, p = 0.002). Nevertheless, the occurrence of dyslipidemia has no remarkable influence on prognosis.
UNASSIGNED: In summary, dyslipidemia correlates with genetic heterogeneity in DLBCL without having a significant influence on survival. This research first connects lipids and genetic subtypes in DLBCL.
UNASSIGNED: This study concluded that 259 patients with newly diagnosed DLBCL and their biopsy specimens were available for molecular typing. Results show that the incidence of dyslipidemia (87.0%, p <0.001) is higher in the EZB subtype than in others, especially hypertriglyceridemia (78.3%, p = 0.001) in the EZB subtype. Based on the pathological gene-sequencing, patients with BCL2 gene fusion mutation are significantly correlative with hyperlipidemia (76.5%, p = 0.006) and hypertriglyceridemia (88.2%, p = 0.002). Nevertheless, the occurrence of dyslipidemia has no remarkable influence on prognosis.
UNASSIGNED: In summary, dyslipidemia correlates with genetic heterogeneity in DLBCL without having a significant influence on survival. This research first connects lipids and genetic subtypes in DLBCL.
摘要：
■弥漫性大B细胞淋巴瘤（DLBCL）是一种高度异质性的非霍奇金淋巴瘤，在临床和遗传方面。诚然，DLBCL按遗传学分为六种亚型，含有MCD，BN2,EZB,N1、ST2和A53。血脂异常与多种实体瘤有关，最近有报道称与血液恶性肿瘤有关。我们的目的是提出一项基于分子亚型的DLBCL血脂异常的回顾性研究。
■这项研究得出结论，259例新诊断的DLBCL患者及其活检标本可用于分子分型。结果表明，血脂异常的发生率(87.0%，p<0.001)在EZB亚型中高于其他亚型，尤其是高甘油三酯血症（78.3%，在EZB亚型中p=0.001)。基于病理基因测序，BCL2基因融合突变患者与高脂血症显著相关(76.5%,p=0.006）和高甘油三酯血症（88.2%，p=0.002)。然而，血脂异常的发生对预后无显著影响。
■总之，血脂异常与DLBCL的遗传异质性相关,对生存无显著影响.这项研究首先将DLBCL中的脂质和遗传亚型联系起来。
■这项研究得出结论，259例新诊断的DLBCL患者及其活检标本可用于分子分型。结果表明，血脂异常的发生率(87.0%，p<0.001)在EZB亚型中高于其他亚型，尤其是高甘油三酯血症（78.3%，在EZB亚型中p=0.001)。基于病理基因测序，BCL2基因融合突变患者与高脂血症显著相关(76.5%,p=0.006）和高甘油三酯血症（88.2%，p=0.002)。然而，血脂异常的发生对预后无显著影响。
■总之，血脂异常与DLBCL的遗传异质性相关,对生存无显著影响.这项研究首先将DLBCL中的脂质和遗传亚型联系起来。
